AI agents are entering 340B workflows without 340B-specific governance
Covered entities and contract pharmacies are introducing AI agents into 340B eligibility determinations, claims capture, split-billing logic, and TPA data reconciliation. These are decision points that HRSA already scrutinizes closely, because errors at any of them can produce duplicate discounts, diversion, or eligibility misclassification. HRSA's program integrity rules prohibit a covered entity from receiving both a 340B discount and a Medicaid rebate for the same drug unit, and restrict 340B-purchased drugs to eligible patients of the covered entity. Audits are built around verifying these two prohibitions through patient-level recordkeeping.
HRSA has not published AI-specific 340B guidance. This does not create a gap in accountability. A covered entity remains fully responsible for eligibility and duplicate discount outcomes regardless of whether a human or an AI agent produced the underlying determination. That places the burden on compliance and AI governance leaders to extend existing 340B controls to AI agents rather than treat AI involvement as a separate technical exception outside the existing compliance program.
Duplicate discount and diversion exposure at AI-assisted decision points
Split-billing arrangements and TPA reconciliation platforms already function as points where duplicate discount and diversion errors originate, because they involve matching a specific dispensed unit to a specific patient and payer status. Inserting an AI agent at these points does not eliminate that risk; it adds another system whose logic must be explainable during an audit.
If an AI agent has simultaneous access to both 340B eligibility data and Medicaid rebate data, an error in that logic can directly produce a duplicate discount. Segmenting that access and requiring tool-call level authorization for any write action to claims or split-billing systems reduces the chance that a single AI agent decision creates exposure across both program integrity requirements at once. This is an access design decision, not an AI ethics or model accuracy question, and it should be evaluated as part of the same architecture review used for other pharmacy claims systems.
Covered entities remain accountable under existing duplicate discount, diversion, and recordkeeping rules whether a human or an AI agent participated in the determination. Runtime controls make those determinations attributable and reviewable.